L
Lasse Steen Ravn
Researcher at Novo Nordisk
Publications - 5
Citations - 4669
Lasse Steen Ravn is an academic researcher from Novo Nordisk. The author has contributed to research in topics: Liraglutide & Type 2 diabetes. The author has an hindex of 4, co-authored 5 publications receiving 3733 citations.
Papers
More filters
Journal ArticleDOI
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso,Gilbert H. Daniels,Kirstine Brown-Frandsen,Peter Lommer Kristensen,Johannes F.E. Mann,Michael A. Nauck,Steven E. Nissen,Stuart J. Pocock,Neil R Poulter,Lasse Steen Ravn,William M. Steinberg,Mette Stockner,Bernard Zinman,Richard M. Bergenstal,John B. Buse +14 more
TL;DR: In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, orNonfatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo.
Journal ArticleDOI
Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial
Steven P. Marso,Neil Poulter,Steven E. Nissen,Michael A. Nauck,Bernard Zinman,Gilbert H. Daniels,Stuart J. Pocock,William M. Steinberg,Richard M. Bergenstal,Johannes F.E. Mann,Lasse Steen Ravn,Kirstine Brown Frandsen,Alan C. Moses,John B. Buse +13 more
TL;DR: It is expected that LEADER will provide conclusive data regarding the cardiovascular safety of liraglutide relative to the current standard of usual care for a global population of patients with T2DM.
Journal ArticleDOI
LEADER 3—Lipase and Amylase Activity in Subjects With Type 2 Diabetes: Baseline Data From Over 9000 Subjects in the LEADER Trial
William M. Steinberg,Michael A. Nauck,Bernard Zinman,Gilbert H. Daniels,Richard M. Bergenstal,Johannes F.E. Mann,Lasse Steen Ravn,Alan C. Moses,Mette Stockner,Florian M.M. Baeres,Steven P. Marso,John B. Buse +11 more
TL;DR: In this large study of type 2 diabetic patients, nearly 25% had elevated lipase or amylase levels without symptoms of acute pancreatitis, and the clinician must take these data into account when evaluating abdominal symptoms in type 1 diabetic patients.
Journal ArticleDOI
Liraglutide and Renal Outcomes in Type 2 Diabetes: Results of the LEADER Trial
E. Raff,Irene Hramiak,Johannes F.E. Mann,Kristine Brown Frandsen,Gilbert H. Daniels,Peter Lommer Kristensen,Michael A. Nauck,Steve Nissen,Stuart J. Pocock,Neil R Poulter,Lasse Steen Ravn,Søren Rasmussen,William M. Steinberg,Mette Stockner,Bernard Zinman,Florian M.M. Baeres +15 more
Journal ArticleDOI
Liraglutid und renale Endpunkte bei Typ 2 Diabetes: Ergebnisse der LEADER Studie
JF Mann,Michael A. Nauck,Stephan Jacob,J Lüdemann,Kirstine Brown-Frandsen,Gilbert H. Daniels,Peter Lommer Kristensen,Steven E. Nissen,Stuart J. Pocock,Neil R Poulter,Lasse Steen Ravn,Søren Rasmussen,William M. Steinberg,Mette Stockner,B. Zinman,Richard M. Bergenstal,M Rieck,Florian M.M. Baeres,Steven P. Marso,John B. Buse +19 more